LGX818 and LEE011 are investigational anticancer drugs being assessed together in this study in patients with melanoma. LGX818 blocks the activity of an abnormal form of a protein called BRAF, which promotes the growth of melanoma. LEE011 blocks a protein called CDK, which tells melanoma cells to divide. LGX818 may be more effective against melanoma when given in combination with LEE011.
The purpose of this study is to assess the safety and effectiveness of the combination of LEE011 and LGX818 when given in patients with locally advanced or metastatic BRAF-mutant melanoma whose cancers continued to grow despite prior therapy with a BRAF inhibitor. Both drugs are taken orally (by mouth).